Operational Excellence (OPEX) Daily Briefing – Wednesday, September 17, 2025: GSK and the $30 Billion Plan in the U.S.: Lessons from Operational Excellence Tools.
Điểm Tin Operational Excellence (OPEX) Mỗi Ngày – Thứ Tư, ngày 17/09/2025: GSK và kế hoạch 30 tỷ USD tại Mỹ: Bài học từ các công cụ trong Operational Excellence.
Welcome to my unique weekday article for the paid subscriber-only edition.
Operational Excellence (OPEX) Daily Briefing – issued on weekdays (Monday to Friday).
Điểm tin Operational Excellence (OPEX) hằng ngày (phát hành các ngày thứ Hai đến thứ Sáu).
This is the bilingual post in English and Vietnamese. Vietnamese is below.
Đây là bài viết song ngữ Anh-Việt. Tiếng Việt ở bên dưới.
Don’t forget the unique BizDecoded series.
🔍 20 Brands, 20 Deep Dives: The Business Behind the Money Machine
Starting from August 20, 2025, get ready for a masterclass like no other.
English:
1. Official Information
On September 17, 2025, pharmaceutical giant GSK (GlaxoSmithKline)—one of the oldest and largest companies in the global pharmaceutical industry—announced a $30 billion investment plan in the U.S. over the next five years【Reuters】.
The investment will focus on three main areas:
Building new plants to manufacture medicines and vaccines in multiple U.S. states.
Expanding R&D centers, with emphasis on next-generation vaccines, cancer therapies, and AI-driven healthcare solutions.
Strengthening domestic supply chains, reducing dependence on raw materials, manufacturing, and logistics from abroad.
It is estimated that this plan will create around 15,000 new jobs, increase U.S. self-sufficiency in pharmaceuticals, and strengthen GSK’s competitive position against rivals such as Pfizer, Moderna, and Sanofi.